



Scan to
Download the App

diginerve
A Jaypee Initiative
Your Guide at Every Step
Video Lectures | Notes | Self-Assessment

Community Medicine Buster

*As per the Competency-based
Medical Education Curriculum (NMC)*

- 10 Years' Solved Question Papers from 30 Universities across India
- 1,000+ MCQs

5th
Edition

**Gautam Sarker
Palash Das**



JAYPEE

Contents

Chapter 1: Concept of Health and Disease	1
■ Definition of health as per WHO and its limitation	1
■ Concept of holistic health	1
■ Spiritual dimension of health	1
■ Relativeness of health	2
■ Spectrum of disease, concept of positive health	2
■ Health and development are interrelated	3
■ Public health and its different phases	3–4
■ Different determinants of health	4–5
■ Agent, host and environmental factors	5–6
■ Multifactorial causation of disease with suitable examples	6–7
■ Web causation of disease	7
■ Diagram and application of different modes of interventions in the natural history of disease	7–8
■ Knowledge of natural history of diseases helps us to prevent disease in the community	8
■ Primordial prevention and different levels of prevention and mode of interventions	9
■ Health promotion	10
■ Concept of information, education and communication (IEC)	10–11
■ Behavior change communication (BCC)	11–12
■ Indicators of health, characteristics of an ideal indicator	12–13
■ List the various indicators of health which directly assess ill health in a community	13
■ Demographic profile of India and discuss its impact on health	14
■ Role of effective communication skills in health and disease	14–15
■ Doctor patient relationship plays a vital role in care of disease	15
■ Meaning of disease control, elimination, extinction and eradication with examples	15–16
■ Different disability rates, sullivan's index with examples, DALY, DFLE	16–17
■ Concept of disability limitations	17
■ Dependency ratio	17
■ Rehabilitation, social rehabilitation and vocational rehabilitation	17–18
■ Principle of prevention	18
■ Early diagnosis and treatment are the main intervention of disease control	19
■ Iceberg phenomenon of a disease	20
■ Well-being and wellness	22
■ Quality of life	20
■ Physical quality life index (PQLI)	20–21
■ Human development index (HDI)	21
■ Global hunger index (GHI)	21–22
■ Human poverty index (HPI)	22
■ Healthy lifestyles	22
■ Lifestyle and healthy ageing	22–23
■ Family medicine/family physician	23
■ Contribution of Edward Jenner, Roland Ross, Louis Pasteur, John Snow, James Lind	23–24
■ International classification of diseases (ICD)	24–25
■ MCQs-57	25

Chapter 2: Relationship of Social and Behavioral Sciences to Health and Disease 31

■ Types of family, stages of family cycle, role of family in health and disease change	31–32
■ Matrilineal family	31
■ Functions of family	32–33
■ Steps of clinico-socio cultural and demographic assessment	33
■ Socioeconomic status (SES)	33–35
■ Cultural factors in health and disease	35–37
■ Social psychology, community behavior and community relationship	37–38
■ Barriers to good health and health seeking behavior	38–39
■ Poverty line	39
■ Social security	39
■ Family is considered as an epidemiological unit	39–40
■ Family as a unit of health	40
■ Social group; crowd, mob, herd, band	40
■ Internship is an example of socialization	40
■ Medical diagnosis, social diagnosis	40–41
■ Social pathology	41
■ Social stress	41
■ Customs	42
■ Culture	42
■ Role of emotions in health and disease	42–43
■ Acculturation, its merits and demerits	43
■ Medical social worker (MSW)	43–44
■ Social mobilization	44
■ Social defense	44–45
■ Social therapeutics measures	45
■ Social control mechanism	45
■ Social medicine and socialized medicine	45–46
■ Crude literacy rate and effective literacy rate are not synonymous	46
■ MCQs-18	46

Chapter 3: Environmental Health Problems..... 49

Water and other environmental problems

■ Meaning of safe water and wholesome water	49–51
■ Sanitary sources of water	49–51
■ Health hazards of water pollution	51
■ Waterborne and water-related diseases	51–52
■ Epidemiology, prevention and control of hepatitis B	52–54
■ Hepatitis B infection should be considered more dangerous than HIV infection	54
■ Australia antigen	55
■ Serological marker of hepatitis B	55
■ Epidemiology and important preventive measures for control of diarrhea	55–57
■ Classification of dehydration	56–57
■ Oral rehydration therapy (ORT)	57–58
■ Common home-made oral rehydration solutions	58–61
■ Preparation of ORS	58
■ Zinc supplementation in management of diarrhea	59–63
■ Consequence of 100 children with diarrhea	60
■ Low osmolarity ORS	61–63
■ Advantages of low osmolar ORS over conventional ORS	62
■ Botulism	64
■ Purification of water in large scale	65

■ Difference between slow sand filter and rapid sand filter	66
■ Purification of water at household level/small scale	66–67
■ Zoogloal layer	67
■ Criteria and standards of drinking water	67–69
■ Bacteriological surveillance of drinking water	69–70
■ Coliform organisms are chosen as indicator of fecal pollution	70
■ Important inorganic chemicals of health significance	71–72
■ Hardness of water	72–73
■ Water conservation and harvesting in urban areas	73
■ Principles of chlorination of water	74
■ Breakpoint chlorination of water	74–75
■ Super chlorination	75
■ Criteria for healthful housing	75–76
■ Overcrowding and its effect on health	75–76
■ Concept of solid waste	76
■ Concept of human excreta	76
■ Different types of latrines	77–78
■ Criteria for a sanitary latrine and principles of septic tank	78–79
■ Modern sewage treatment	79
■ Biological treatment of sewage	79
■ Sanitary barrier and its public health importance	79–80
■ Soakage pit/disposal of wastewater at household level	79
■ Sanitary landfill	80
■ Causes of air pollution and health hazards	80–81
■ National air quality index	82
■ Smog	82
■ Noise and hazard of noise pollution	82–83
■ Hazards of radiation	83
■ Radiation hygiene	84
Vector-borne diseases:	
■ Role of vectors in the causation of diseases	84
■ Public health importance of vector-borne diseases	85
■ Principle of vector-control program	85
■ Strategies under national vector borne diseases control program	85
Malaria:	
■ Guidelines for treatment of uncomplicated malaria	85
■ Diagnosis and treatment strategies of malaria as per national strategic plan (2017–22)	86–87
■ Reasons of persistence of malaria	88–89
■ Importance of ABER and API	89
■ Epidemiology of malaria	89–90
■ Mode of transmission and chemoprophylaxis of malaria	90–91
■ Short-term control measures for an outbreak of malignant malaria	92
■ Long-term control measures for an outbreak of malignant malaria	93
■ Malariometric measures/indices	93–94
■ Slide positivity rate	94
■ Surveillance of malaria	94–95
■ Major epidemiological types of malaria	95
■ Treatment for vivax malaria	95–96
■ Factors responsible for resurgence of malaria	96
■ Difference between mosquito and sand fly	97
■ Man-made malaria	97
■ Comment on malaria week and WMD	97

Filaria:

- Epidemiology of lymphatic filariasis and its control 97–98
- Mass drug administration in filariasis 98
- Filariasis never causes explosive epidemic 98
- Night blood examination 99
- Assessment of filarial control program 99

Dengue:

- Epidemiology and clinical presentations and classification of dengue 99–101
- Laboratory diagnosis of dengue 101
- Measures for control dengue outbreak 101
- Dengue shock syndrome 101

Chikungunya:

- Clinical feature, diagnosis, treatment, control of chikungunya fever 102–103

Japanese encephalitis:

- Epidemiology, clinical features, control of Japanese encephalitis 103–104
- Amplifiers of the virus 103
- Epidemiological aspects of kala-azar. Discuss the strategies for control of disease 105–106

Kala-azar:

- Drug of choice of kala-azar 106
- Causes of resurgence of kala-azar 106
- Integrated vector management (IVM) 106–110
- Use of long-lasting insecticidal bed nets (LLINs) 108
- Malaria vaccine 109–110
- Identifying features of vectors of public health importance 110–111
- Life cycles of malarial parasite 111–112
- Mode of action, application cycle of commonly used insecticides and rodenticides 113–115
- Trapping in relation to rodents 115
- Arthropod-borne diseases 115
- Blanket treatment with examples 116
- Cyclops 116–117
- Chandler's index 117
- Mass drug administration for soil transmitted helminths 117
- Criteria's for successful parasitism 117–118

Ventilation and other issues:

- Types of ventilation, mechanical ventilation, exhaust ventilation 118–119
- Comfort zone, corrected effective temperature 119
- Heat stress indices 119–120
- Greenhouse effect 120
- Causes and effects of global warming 121
- High altitude/mountain sickness 121
- Day light factor 121
- **MCQs-125** 122

Chapter 4: Principles of Health Promotion and Education..... 132

- Methods of organizing health promotion and education activities 132
- Different methods of health education communication 132–133
- Channels of communication 133
- Group discussion 133–134
- Focus group discussion (FGD) 134
- Panel discussion 134–135
- Symposium 135
- Mass communication 135

■ Folk media	135
■ Workshop	135–136
■ Principles of communication process	136
■ Different types of communication	137
■ Different audio-visual AIDS in health communication	137
■ Stages of learning	137–138
■ Social marketing	138–139
■ Objectives of health education	139
■ Principles of health education	139–140
■ Concept of counseling and its skills	140
■ GATHER approach	141–142
■ Role of (pretest and post-test) counseling in controlling HIV/AIDS	142
■ Describe kinds of interview, questionnaire/schedule	142–143
■ Demonstration	143
■ Telemedicine is now an important field of medical communication	143
■ Common barriers of communication	143–144
■ Attitude and role play	144
■ Health education is not a health propaganda	144–145
■ MCQs-19	145
Chapter 5: Nutrition	148
■ Common sources of various nutrients and special nutritional requirements	148–149
■ Different methods of diet survey	149–150
■ Nutritional assessment	150
■ Anthropometry is an effective method for nutritional assessment in under five children	150–152
■ Common nutritional problems in India	153
■ Malnutrition definition, epidemiology of malnutrition, classification of PEM, causes of PEM	154–155
■ Different strategies in terms of levels of prevention	155
■ Anemia Mukht Bharat strategy, 6 × 6 × 6 strategy	157–158
■ Causes and detrimental effects of nutritional anemia	160
■ Anemia prophylaxis and treatment	160
■ Action plan to conduct IEC campaign for anemia prevention	162–164
■ 12 by 12 initiative for anemia control program	164
■ Zinc-related disorders	164
■ Enlist disorder caused by Iodine deficiency	164–165
■ Vitamin A deficiency diagnosis, its prevention and treatment	165–166
■ WHO classification of vitamin A deficiency	165–166
■ Extraocular manifestations of vitamin A deficiency	166
■ Short-term high dose vitamin A supplementation	166–167
■ Synopsis of water-soluble vitamins	167–168
■ Fluorine is often called two-edged sword	168
■ Principles of nutritional rehabilitation	169
■ Principles of nutritional education	170
■ Difference between growth monitoring and nutritional surveillance	171
■ Community nutrition program available in India	171
■ Objectives of services provided and beneficiaries under ICDS program	171–172
■ Essentials of school health services	173–176
■ Nutritional program associated with school health services	174
■ Mid-day meal program	175
■ National nutritional policy	175
■ Food safety, food standards, milk borne diseases and pasteurization	176–179
■ Food additives and food adulteration	180

■ Food enrichment, fortification of food and iodization of salt	180–181
■ Problems of adolescents, national programs concerning its improvement	181
■ Body mass index (BMI)	182
■ Different types of food toxicants and consequent diseases	182–183
■ Growth chart, its uses, growth charts for boy and girls	185–187
■ Difference between Marasmus and Kwashiorkor	188
■ Child development project officer (CDPO)	188
■ Anganwadi worker (AWW)	188–189
■ Village health and nutrition day (VHND)	189
■ Parboiled rice is nutritionally superior to milled rice, nutritional profile of cereal	190
■ Balanced diet, prudent diet	190–191
■ Food-guide Pyramid	191
■ Reference protein and assessment of quality of protein	192
■ Limiting amino acids	192
■ Combining rice and pulse in diet is a good practice	193
■ Important sources of dietary fiber	193
■ Essential fatty acid, its dietary source and functions	193
■ Indian reference man and women	193–194
■ Components of IYCF, complementary feeding and weaning	194–196
■ MCQs-89	196

Chapter 6: Basic Statistics and its Applications and Research Methodology204

■ Data with suitable examples and scales of measurement of data	204–205
■ Methods of data collection	205
■ Data analysis and interpretation, presentation of statistical data	208
■ Application of elementary statistical methods	212
■ Measurement of central tendency	212–213
■ Statistical averages, mean, median and mode	213–214
■ Measures of dispersion	214–215
■ Frequency distribution	216
■ Normal curve, Gaussian curve, standard normal curve	217–218
■ Spread, shape (skewness, kurtosis)	219–220
■ Sampling technique	220–221
■ Hypothesis, null hypothesis, type I error and type II error in research	226
■ Chi-square test	228–229
■ Students t-test	229
■ Research question, its components and framing	231–233
■ Uses of biostatistics in public health	233
■ Hospital statistics are considered a poor guide for estimation of a disease frequency	233
■ MCQs-148	234

Chapter 7: Epidemiology246

■ Epidemiology definition, its objectives, principle, uses/application of epidemiology	246–247
■ Sources of epidemiological data	247
■ Classify/categorize the types of epidemiological studies/methods	249
■ Steps in conducting a descriptive epidemiological study	249–250
■ Uses of descriptive epidemiology	250
■ Different types of time trends in disease occurrence with suitable examples	250–251
■ Mention the different type of epidemics with suitable examples	250–251
■ Changing concept of epidemic	251–252
■ Time distribution	251
■ Place distribution	251

■ Local distribution of disease/spot map	252
■ Person distribution	252
■ Descriptive cross-sectional study to assess the extent of overweight and obesity	253–254
■ Steps in conducting a case-control study with an appropriate example	254–255
■ Case-control study to find out the association between smoking and lung cancer	255–256
■ Cohort study and its type	256
■ Indications for cohort studies	256–257
■ Different steps (elements) of a cohort study	257
■ Differences between case-control and cohort study	257–258
■ Advantage and disadvantage of case-control and cohort study design	258
■ Different types of analytical studies and steps of randomized control trial (RCT)	259–260
■ Blinding in epidemiological studies (RCT)	260
■ Association and causation in epidemiological studies	260
■ Biases of epidemiological studies and its elimination	263–264
■ Different modes of transmission of diseases	264–265
■ Biological transmission	265
■ Source and reservoir of infection its dynamics and modes of disease transmission	265
■ Methods of controlling reservoir	267
■ Measures for prevention and control of communicable diseases	267–268
■ Measures for prevention and control of noncommunicable diseases	268–269
■ Basic measurements on epidemiology (rate, ratio and proportion)	269–270
■ Incidence and prevalence of disease with their relation, point and period prevalence	270
■ Difference between incidence and prevalence	270
■ Measurement of morbidity/morbidity indicators	271
■ Secondary attack rate (SAR)	271–272
■ Uses and limitation of mortality data	272
■ Mortality indicators	272
■ Crude death rate and its limitation	272–273
■ Age specific indicators of health	273
■ Direct and indirect standardization	273
■ Standardized mortality ratio (SMR)	273–274
■ Proportional mortality rate	274
■ Case fatality rate and its significance	274–275
■ Life expectancy at birth	275
■ Under-5 mortality rate is a good index of social development of a country	275
■ A few cases of jaundice cases in boys' hostel, following investigation	275–277
■ Application of computers in epidemiology	279
■ Role of IT in changing scenario of public health	279–280
■ Epidemiological triad and triangle of epidemiology	280
■ Endemic and epidemic with suitable examples	280–281
■ Difference between epidemic and outbreak	281
■ Difference between epidemic, endemic, pandemic and sporadic	281
■ Difference between iatrogenic nosocomial and opportunistic infection	282
■ Hospital-acquired infection	282–283
■ Man today is viewed as an agent of his own disease	283
■ Confounding in epidemiological study	283
■ Importance of cross-product ratio/odds ratio	283
■ Define relative risk and attributable risk	283–284
■ Population attributable risk	285
■ Epidemiologically carriers are more dangerous than cases	285
■ Difference between primary case and Index case	285
■ Vector	286

■ Source and reservoir are not always synonymous	286
■ Specimen for death (international) certificate	287
■ Droplet infection and airborne infection	287–288
■ Pandemic	288
■ Zoonosis	288
■ Difference between monitoring and surveillance with examples	288–289
■ Epidemic curve	289
■ Usefulness of knowing incubation period	290
■ Serial interval	291
■ Injection safety is important for the recipient, provider and community	291
■ Methods (types) of disinfection	291–292
■ Define screening its types, uses of screening and criteria for screening of diseases	292–293
■ Criteria of the test to be applied/validity of screening test	293–294
■ Cancer cervix screening in a PHC area	294–295
■ Screening and case finding are not synonymous	296
■ Difference of screening and diagnostic test	296
■ Sentinel surveillance of disease is better than periodic mass screening	296–297
■ Significance of true positive value in screening test	297
■ Significance of false positive in screening test	297–298
■ Interpretation of false negatives of a screening test	298
■ Sensitivity and specificity	298
■ Lead time in screening of a disease	299
■ MCQs-208	299

Chapter 8: Epidemiology of Communicable and Noncommunicable Diseases.....319

■ Principles of planning, implementing and evaluating control measures for disease	319
■ Essential laboratory tests at the primary care level for communicable diseases	321
HIV/AIDS/STDs/STIs:	
■ Epidemiology of AIDS	321–322
■ National AIDs control program	322–323
■ Package of services provided under NACP- IV	323–324
■ Name common STDs	324–325
■ Syndromic management and its protocol	325–326
■ Role of VCTC/ICTC in controlling HIV/AIDS	326
■ HIV sentinel surveillance	327
■ Suraksha clinic	327–328
■ WHO criteria for diagnosis of AIDS	328
■ AIDS related complex	328–329
■ Mention modes of transmission of HIV/AIDS/STIs	329
■ List vertically transmitted diseases	329–331
■ Prevention of parent to child transmission	329–331
■ Role of high risk group and bridge population in HIV transmission	331
■ HIV is behavioral disease	331
■ Various RTI/STI syndromes	331–332
■ Common complication of STDs	332
■ Risk factors of HIV/AIDs	332
■ ICTC should be supported by ART/Link ART center	332–333
■ Opportunistic infections in AIDS	333
■ Window period	333
■ Contact tracing in STIs	333
■ Guidelines for PEP in HIV/AIDS	334
■ Universal precaution	335
■ HIV-TB collaboration activities are extremely important for control of HIV and TB	335

Rabies:

- Epidemiological factors and prevention of rabies 335–336
- Postexposure prophylaxis (PEP) of rabies 337
- Passive immunization with rabies immunoglobins 338
- Active immunization with ARV 338
- Pre-exposure prophylaxis 339
- Measures for minimizing human rabies in an area 339
- Fixed virus 339

Plague:

- Diagnosis of plague and its control measures 339–341
- Blocked/partial blocked fleas 341

Leprosy:

- Epidemiology of leprosy 341–342
- Cardinal signs, diagnosis, complications and treatment (MDT) of leprosy 342–343
- National leprosy eradication program 344–345
- Different modes of intervention under levels of prevention in leprosy 346–347
- Different presentation of leprosy in OPD 347
- Leprosy eradication is very difficult to achieve 347–348
- Indicators used by the health workers to assess the disability of leprosy cases 348

Tuberculosis:

- Epidemiology of tuberculosis 348
- Various components of DOTS strategy 349
- National program on control of tuberculosis in India 349–352
- Policy updates and new initiatives in NTEP 354
- Cardinal symptoms for diagnosis of pulmonary tuberculosis 354–355
- Diagnostic algorithm for TB and daily dose schedule (FDC) as per weight band 355–357
- Technique for sputum collection from adult and children 356
- Case definitions of TB 356
- Drug schedule for multidrug resistance/rifampicin resistance TB cases 360
- Levels of prevention and mode of interventions as applied to pulmonary tuberculosis 360–361
- Common side effects of 1st line antitubercular drugs 362
- Tuberculosis is an old disease but new threat 362
- Effect of COVID-19 on tuberculosis 362–363
- DOTS plus 363
- Isoniazid (INH) preventive therapy 363

Poliomyelitis:

- Epidemiology of poliomyelitis 363–364
- Acute flaccid paralysis, strategies its eradication, environmental surveillance 364–366
- Levels of prevention and modes of intervention can be applied to poliomyelitis 366
- Immunization for travelers on poliomyelitis 366–367
- Provocative poliomyelitis 367

Yellow fever:

- Measures to prevent entry of yellow fever into India 367–368
- India is yellow fever receptive area 368
- *Aedes aegypti* index 368

Others:

- SAFE strategy for trachoma 368
- Inappropriate and inadequate use of antibiotics leads to antimicrobial resistance 369

Noncommunicable diseases:

- Essential laboratory tests at the primary care level for noncommunicable diseases 369
- Major “risk factors” responsible for sharing noncommunicable diseases 369–370
- Noncommunicable disease of public health importance 370

Diabetes mellitus:

- Epidemiology of diabetes 371
- Classification of diabetes mellitus as adopted by WHO 371–372
- Diagnostic criteria for diagnosis of diabetes mellitus 372–373
- Levels of prevention and modes of intervention in the context of diabetes 373–375
- Life style management to prevent diabetes mellitus 374
- Preventive measures those having family history of diabetes 375
- Different epidemiological determinants/risk factors of diabetes 375–376
- Prevention and control of type II diabetes mellitus 376–377
- Complications (macrovascular and microvascular) of diabetes mellitus 377
- Self-care in diabetes mellitus 378
- Discuss the role of diet in the management of diabetes 378
- Hypertension 378
- Epidemiology of hypertension 378–379
- Modifiable and nonmodifiable risk factors and preventive measures of hypertension 379–381
- Research project on “prevalence of hypertension among medical students of your institute” 381–382
- Rules of halves 382–383
- Tracking of blood pressure 383
- Dash diet and its role in prevention of hypertension 384–385

Coronary heart disease:

- Risk factors of coronary heart disease (CHD) 385
- Measurement the burden of coronary heart disease 387

Rheumatic fever and rheumatic heart disease:

- Burden and natural history of RHD 387–388
- RH and RHD diagnosed, based on revised Jones criteria 388
- Prevention of RH and RHD 388

Obesity:

- Definition of obesity and overweight its prevent and control 389

Cancer:

- Multifactorial etiology of cancer, basic approach to control of cancer 390–391
- Cancer registry 391–392
- Early (danger/warning) signs of cancer 392
- Cancer education 392
- Methods of screening for cancer 393–395
- Common causes of cancer among males and females in India 395–397
- Epidemiology of carcinoma cervix 395
- Epidemiology and prevention of breast cancer 397
- Micronutrient in cancer 398
- Objectives, components and strategies of NPCDCS 398
- Overview of NP-NCD 398
- Role of diet in various diseases, add a note on diet and cancer 400–401
- Tobacco control legislation in India 401–402
- Passive smoking 402

Blindness:

- Major causes of blindness in India, strategies adopted for control of blindness 402–404
- Structure of operation for vision 2020 405
- Preventive blindness 405

Road traffic accident (RTA):

- Epidemiology of RTA in India its common causes and preventive measures 406–408

Others:

- Domestic accidents with its causes 408–409
- Epidemiology, risk factors, early clues for patients, first aids, and antivenom 409–410

■ Integrated disease surveillance program (IDSP)	411
■ Training of health workers in disease surveillance	412
■ Principles of management of information systems	413
■ MCQs-93	414

Chapter 9: Demography and Vital Statistics, Population Stabilization and Medical Genetics.....423

■ Definition of demography and different demographic cycles	423
■ Principles of demography	424
■ Define population explosion, demographic trends in India	424–425
■ Demographic bonus, burden	425
■ Demographic dividend	425–426
■ Population doubling time	426
■ Population dynamics of India and its consequences	427
■ Interpretation of demographic indices including birth rate, death rate, fertility rates	427
■ Net reproductive rate and its significance	428
■ Factors responsible for high fertility in India, control strategy	429–430
■ Factors behind the declining of the sex ratio, measures its correction	430–431
■ Characteristics of age and sex composition of population	431
■ Methods of population control	432
■ National population policy (NPP), 2000	432–433
■ Birth and death registration	434
■ Census	435
■ Sample registration system (SRS)	435
■ National family health survey (NFHS)	436
■ Demographic gap	437
■ Age at marriage and its significance	437
■ Eugenics measures	438
■ Genetic counseling	438
■ Explain genetic diseases	440
■ Turner's syndrome	440
■ Premerital genetic counselling on sickle cell positive	442
■ Gene therapy	443
■ Human genome project	443
■ Role of genetic predisposition in common diseases	443
■ MCQs-30	443

Chapter 10: Reproductive, Maternal, Newborn, Child, Adolescent Health and

Nutrition (RMNCAH+N)447

■ Current status of reproductive and maternal health	447
■ Common local customs and practices during pregnancy, childbirth, lactation	447
■ Child survival and safe motherhood (CSSM) program	449
■ Paradigm shift	450
■ Target free approach/community need assessment (CNA) in RCH	450
■ Janani-shishu suraksha karyakaram (JSSK)	451
■ Pradhan mantri surakshit matritva abhiyan (PMSMA)	451
■ Surakshit matritva aashwasan (SUMAN)	451–452
■ LaQshya Program	452
■ Janani suraksha yojana	452
■ Reproductive, maternal, neonatal, child, and adolescent health (RMNCH +A) program	452–454
■ Goals and targets of RMNCH +A	453
■ RMNCH+A interventions	453
■ RCH services are provided through different levels of healthcare facilities in blocks	454–455

■ Antenatal care, the objectives and components of antenatal care	455
■ Most common postnatal complications	457
■ Antenatal investigation	457
■ Prevention and control of infant mortality	458–459
■ Specific health protective measures in antenatal care	460–461
■ Essential obstetric care, services delivered under essential obstetric care	461
■ Birth preparedness and complication readiness (BPCR)	461–462
■ Different maternal health problems in India	462
■ Indications of MCH care	462
■ Define maternal mortality ratio and maternal mortality rate	463–467
■ Important medical causes and factors (social) related to maternal mortality	463
■ Measures to prevent and control maternal deaths in rural community	463
■ Five cleans and its importance	467
■ Strategies adopted for prevention of neonatal tetanus	468
■ Nutritional requirement during pregnancy and lactation	469
■ Plan antenatal services at primary health centre (PHC) level with 30,000 population	469–470
■ Measure to reduce postpartum hemorrhage in a block	470–471
■ Measure to increase institutional delivery in a district	472
■ Maternal death review at community level	473
■ Factors affecting IMR and measures for its prevention	473
■ Neonatal mortality prevention	475
■ Causes and prevention of perinatal mortality	476
■ Manpower available at block level for delivering the primary healthcare	477–478
■ Home-based newborn care	478–479
■ Functions of an under-five clinic	480–481
■ Low birth weight babies and its prevention	481–482
■ Baby friendly hospital initiative (BFHI)	482–483
■ Advantages of exclusive breastfeeding	483–484
■ Congenital rubella syndrome	484–485
■ Mother and child are one unit	485
■ Crèches	485–486
■ Newborn care	486–487
■ India newborn action plan	487
■ Growth and development are not synonymous	488
■ Kangaroo mother care	488–489
■ Rooming-in	489
■ Juvenile delinquency	489–490
■ Child placement	490
■ Child trafficking	490
■ High-risk pregnant mothers	490–492
■ Method of screening	492
■ “At risk” infants	492–493
■ Rashtriya bal swasthya karyakram	493
Family planning methods:	
■ Contraceptives methods	494–495
■ Male condom and female condom	494–495
■ Social marketing of condoms	495–496
■ Conventional contraceptives with examples	496
■ Combined pills	497
■ Management of missed pills	497
■ Noncontraceptive benefits of oral contraceptives	498–499
■ Knowledge of contraceptives among adolescent	499

■ Newer contraceptives	499–500
■ Centchroman	499
■ Hormonal contraceptives	500
■ Injectable contraceptives	500–501
■ Intrauterine devices	501–503
■ Ideal candidate for use of IUD	503–504
■ Emergency contraception/back up contraceptive	504–505
■ No scalpel vasectomy	506
■ Postoperative advice following vasectomy	506
■ Safe methods (rhythm method)	506
■ Cafeteria approach in family planning	507
■ Family planning method for the couples	507–508
■ Couple protection rate	510–511
■ Scope of family planning services	511–512
■ Health benefits of family planning	512
■ Traditional birth attendants	512
■ Unmet need for family planning	512–513
■ Eligible couple and target couples	513
■ Contraceptive prevalence rate	513
■ Pearl index	513–514
■ Evaluation of family planning program	514
■ Medical termination of pregnancy Act	514–515
■ PC and PNDT Act	515
Immunization and vaccine related Issues:	
■ Mission Indradhanush	515–516
■ National immunization schedule of India	516–516
■ Vitamin A prophylaxis schedule	518
■ Mother and child protection card (MCPC)	518–521
■ Causes of adverse events following immunization (AEFI)	522–523
■ Line listing, an outbreak of measles in one tribal block	524–525
■ Epidemiology, clinical features, major complications, treatment of measles in children	525
■ Clinical feature of measles along with description of rash	525–526
■ Complications of measles	526
■ Appropriate health education plan for measles and rubella vaccination campaign	527–528
■ Concept of cold chain and reverse cold chain, cold chain equipment	528–530
■ Difference between active and passive immunity	531
■ Universal immunization program	531
■ Vaccine preventable diseases and vaccines under uip	531–532
■ Herd immunity with examples	532
■ Advantages of using auto-disable syringes in national immunization program	533
■ Differentiate between live and killed vaccine	533
■ Vaccine vial monitor (VVM)	534
■ Rotavirus vaccine (RVV) and its rationale of use	534–536
■ Pneumococcal conjugate vaccine	536
■ Japanese encephalitis (JE) vaccine/inactivated JE vaccine	536–537
■ Inactivated polio vaccine (IPV)	537–538
■ Difference between salk and sabin vaccine	538
■ Intensified pulse polio immunization (IPPI)	538
■ Risk of VAPP and VDPP and future plan of polio immunization	539
■ Role of IPV in polio eradication	539
■ Switch from trivalent to bivalent OPV	539–540
■ Shake test	540–541

■ BCG vaccine, phenomena after BCG vaccination	541
■ Mantoux test	541
■ Hepatitis B vaccine, its schedule for children and rationality of giving in infants	542
■ Pentavalent vaccine	542–543
■ Measles vaccine and its rationality of use at 9 months of age	543
■ Epidemiologically measles is eradicable	543–544
■ MMR vaccine	544
■ Difference between chickenpox and smallpox	544–545
■ Chickenpox and its prevention	545
■ 17D vaccine	545–546
■ Eradication of tetanus is not practicable	546
■ Candidate vaccine	546–547
■ Describe different phases in clinical trial of vaccines	547
■ Influenza vaccine	547
■ Viva (oral) questions	547
■ Integrated management of neonatal and childhood illness (IMNCI)	551
■ IMNCI guidelines principles	552
■ F-IMNCI	555
■ Problem of ARI	555
■ Objectives of NFPP	557
■ Physiology, problems of adolescents, principles of adolescent health and clinical management	558
■ Rashtriya kishor swasthya karyakaram including ARSH	561
■ Gender issues and women empowerment	562
■ MCQs-142	563

Chapter 11: Occupational Health575

■ Occupational health hazards, their risk factors and its preventive measures	575
■ Medical, engineering measures and legislative measures	576–577
■ Silicosis and its preventive measures	577–578
■ Pneumoconiosis, influencing factors, causative factors and its control and prevention	579–580
■ Farmer's lung	580
■ Hazards of agricultural workers and its prevention	580–581
■ Occupational environment, ergonomics	581
■ Indian factories Act, 1948 and its recommendation	582
■ Eligibility criteria for enrolling in ESI scheme and its benefits	582–583
■ In ESI scheme, employers are also benefited	584
■ Occupational disorders of health professionals and their prevention	584–585
■ Respirable dust and its importance	585
■ Prevention and control of inorganic lead poisoning	585–586
■ Health Insurance Scheme	586
■ Thermal indices comfort	586–587
■ Problems of industrialization and urbanization and measure for its improvement	587
■ Sickness absenteeism and prevention	587–588
■ Child labor	588
■ Causes and types of occupational cancer and its prevention	588–589
■ Causes and prevention of occupational dermatitis	589–590
■ MCQs-30	590

Chapter 12: Geriatric Health593

■ Concept of geriatric services	593
■ Health problems of geriatric population	593–594

■ Prevention of health problems of aged population	594–595
■ National program for elderly	595–596
■ Package of services available at different levels under NPHCE	596
■ MCQs-3	597

Chapter 13: Disaster Preparedness and Management.....598

■ Concept of disaster management	598
■ General effects of disaster	599
■ Health effects of disaster	599
■ Preparedness plan to mitigate hazards due to disaster	600
■ Disaster management cycle and its components	601–602
■ Man-made disasters in the world and in India	602–603
■ National disaster management authority	603–604
■ Triage	604
■ Vaccination in disaster	604–605
■ MCQs-9	605

Chapter 14: Hospital Waste Management607

■ Classification of hazardous waste	607
■ Different types of biomedical waste generated at source measures for their safe disposal	607–611
■ Guidelines for handling and disposal of waste generated from COVID-19 patients	609–611
■ Different methods of solid waste disposal with special reference to rural area	613–614
■ Various schedules in biomedical waste management rules 1998 and 2016	615
■ Principles of biomedical waste management	616
■ Handle contaminated metal instruments	616
■ Health hazards of biomedical waste	617
■ Disposal of sharp waste in health care setting	617
■ MCQs-22	618

Chapter 15: Mental Health.....621

■ Concept of mental health	621
■ Warning signs of poor mental health	621–622
■ National mental health program	622–623
■ Alcohol control program	623
■ Drug addiction, de-addiction	624–625
■ Drug dependence and prevention strategies	625
■ MCQs-8	625

Chapter 16: Health Planning and Management.....627

■ Concept of planning	627
■ Planning, administration, management, goals, objectives, target	628–629
■ Planning cycle	628–629
■ Qualitative and quantitative methods of health management technique	629–631
■ Comparison between PERT and CPM	632
■ Health planning in India and national policies related to health and health planning	633
■ Bhore committee	634
■ National health policy-2017	636–639
■ Management consist of four basic principles	640
■ Prioritization is important step in health planning	640
■ Feedback is very important in health planning	640–641
■ SWOT analysis	641–642

■ Components of evaluation process	642
■ Budgeting/zero budget approach	643
■ Cost-effective analysis and cost-benefit analysis are not synonymous	644
■ Health economics	644–645
■ Niti ayog	645
■ MCQs-26	645

Chapter 17: Health Care of the Community648

■ Delivery of primary health care in rural areas/in a block level	648–649
■ Measurement health of people of a village near a primary health center	649–650
■ Medical care and health care not synonymous	652
■ Community diagnosis	652
■ Community treatment	652–653
■ Primary health care	653
■ Principles of primary health care	653
■ Elements/components of primary health care	653–654
■ Primary health care basically the responsibility of the state	655
■ Millennium development goals (MDGs)	655
■ Sustainable development goals (SDGs)	659
■ Difference between primary health center and a hospital	662
■ Organogram of health care delivery in India	662–663
■ Various healthcare systems in India	663
■ Comprehensive health care	663
■ Functions of PHC relating various activities of district health society	663–664
■ Functions of block primary health centre	664–665
■ Indian public health standard (IPHS)	665–666
■ Comparison of health situation in two communities	670
■ Ayushman Bharat Health and Wellness Centre	671
■ Subcenter, primary health center	672
■ Functions of medical officer of a block primary health center	672
■ First referral unit (FRU)	672–673
■ Difference between comprehensive health care and curative health care	674
■ Difference between PHC and CHC	674
■ ASHA/eligibility criteria for selection of ASHA	674–675
■ Populations catered in relation to health—in a village, subcenter, PHC, BPHC or CHC	675
■ Preventive services offered by your medical colleges and hospitals	676
■ Accessibility cannot be equated with acceptability of health services	676
■ Three tier structure in panchayat raj	676–677
■ List uses of hospital records	677
■ Medical audit	677
■ Job description of multipurpose health worker/health worker female/ANM	678
■ Deprofessionalization of medicine	679
■ Indigenous systems of medicine in India/AYUSH	679
■ Central government health scheme (CGHS)	679
■ MCQs-42	680

Chapter 18: International Health and its Regulations684

■ Concept of international health	684
■ Works of multilateral and bilateral agencies	684–685
■ Voluntary health agency	685
■ Networking with voluntary agency play an important role in health care delivery	685
■ International organizations have many roles to play in control of pandemic	685

■ Nongovernment organization and its role in community health	685–686
■ WHO	686–687
■ UNICEF	687–688
■ CARE	688
■ World Bank	688
■ Indian Red Cross	688–689
■ Rockefeller Foundation	689–690
■ Ford Foundation	690
■ FAO	690
■ ILO	690
■ UNDP	691
■ DFID	691
■ Emporiatrics	691–692
■ Difference between quarantine and isolation	692
■ Quarantine and isolation are not synonymous	693
■ Notification of disease	693–694
■ Nothing on earth is more international than disease	694
■ MCQs-21	694

Chapter 19: Essentials Medicines and Rational Use of Drugs697

■ Concept of essential medicine list (EML)	697
■ Roles of essential medicine in primary healthcare	698
■ Counterfeit medicine and its prevention	698–699
■ Prevention of counterfeit medicines in India	699
■ MCQ-1	694

Chapter 20: Recent Advances in Community Medicine700

■ List important public health events of last 5 years	700
■ Emerging and re-emerging diseases	701
■ Zika virus	701
■ Epidemiology, clinical features, diagnosis and prevention and control of Swine flu	702–703
■ Antigenic shift and antigenic drift	703
■ Epidemiology and prevention of Ebola virus disease	703–704
■ Bioterrorism	704–705
■ Various issues during outbreaks and their prevention	705–706
■ Clinical features, modes transmission, diagnosis and prevention of COVID-19	706–709
■ Available vaccines against COVID-19	709
■ Awareness about laws pertaining to human organ transplantation Act and its implications	709–710
■ Clinical establishment Act (CEA), 2010	710
■ MCQs-6	710

Chapter 21: AETCOM.....711

■ Rights of a physician and patient	711
■ Roles of an Indian Medical Graduate	711–712
■ Basic qualities of a good physician	712
■ Importance of lifelong learning of a physician	712
■ Health is our right	712–713
■ Concept of fiduciary duty	713
■ Steps of effective communication	714
■ Fundamentals of a good doctor-patient relationship	714–715
■ Nonjudgemental and empathetic manner while communicating with a patient	715–716
■ Importance of confidentiality in healthcare practices	716

■ Exceptions of confidentiality in healthcare practices	716
■ Definition of professionalism, difference between empathy and sympathy	717
■ Empathy for a patient	718
■ Breaking a bad news to a patient	718
■ SPIKES protocol	718–719
■ Medical error in clinical practice and correct approach to disclose it	719–720
■ Consequence of failure to disclosure of medical errors	720
■ Effective communication in preventing medication error	720–721
■ Four pillars of medical ethics with examples	721
■ Ethical issues related to informed consent	721–722
■ Principles and components of “Informed consent” in patient care	722–723
■ Harm in medical practice, types of harms in medical ethics with example	723
■ Autonomy and paternalism, responsibilities of patients and doctors in decision making	723–724
■ Case-based scenario on ethical aspects	724–725
■ Case-based scenario on ethical aspects and blood transfusion	724–725
■ Handling a patient ethically who is upset with treatment received from another physician	725–726
■ Tackling noncompliance of patient to your prescription	726
■ Tackling a situation where patient is angry due to the long time spent in the waiting room	727
Chapter 22: Family Adoption Program.....	728
■ Rationale	728
■ Objectives	728
■ Activities under FAP in different professional period	729–732
■ Health camp under FAP	733–735
Index	737

Recent Advances in Community Medicine

CM20.1: List important public health events of last five years.

Q1. List important public health events of last 5 years.

Ans: International events:

- ICD-11 released in 2018 to be implemented in 2022
- Ebola virus disease—declared as Public Health Emergency of International Concern in July 2019 by WHO.
- Novel Coronavirus Pandemic (Covid-19) with epicentre at Wuhan, China and spreading to 220 other countries of the world
- WHD 2021—Building a fairer healthier world for everyone to eliminate health inequities
- Vaccine against COVID-19 developed and launched in 2020
- 1st Malaria vaccine—MOSQUITOIRIX approved by WHO in October, 2021
- WHO approved Covaxin for emergency use on 3rd November, 2021

National events

Natural disasters:

- Unprecedented floods in Kerala in 2018 and 2019
- Cyclone Fani struck Odisha on May, 2019
- Supercyclone—Amphan struck West Bengal and Odisha with massive devastation
- Severe cyclone Nisarga struck Mumbai and Gujarat in June, 2020
- Cyclone Gulab hit Andhra Pradesh, Telangana and Odisha in September, 2021

Outbreaks/Epidemics:

- Covid-19 pandemic in 2020
- Outbreak of Nipah virus in Kerala in 2018
- JE/AES outbreak in Muzaffarpur in Bihar in 2019
- Vaccine against Covid-19 developed. India developed Covishield, Covaxin
- Zika virus disease outbreak in Kerala in July, 2021
- National Covid vaccination drive launched on 16 January, 2021

New program and policies:

- Prime Minister's Jan Arogya Yojana (PMJAY) launched in September, 2018
- National Nutrition Mission-Poshan Abhiyan and Anemia Mukta Bharat in April, 2018
- Guidelines on programmatic management of drug resistant TB in India, 2019
- All oral H mono/poly, shorter and longer MDR-TB regimen started in 2020
- CNNS survey 2016-18 released in 2019
- National Medical Commission Act, 2019
- Competency-based undergraduate curriculum rolled out along with AETCOM course in 2019-20
- Ayushman Bharat Health Infrastructure Mission (ABHIM) launched in October 2021.

Q2. Describe emerging and re-emerging diseases.

(AKUB, 2022; AFUH, 2022; VBUJH, 2022; MU, 2023; GNSUB, 2023)

Ans: Emerging diseases:

- HIV/AIDS
- Severe acute respiratory syndrome (SARS)
- COVID-19 Pandemic
- Bird flu or avian influenza
- Pandemic influenza
- Multidrug resistant tuberculosis (MDR/XDR)
- Japanese encephalitis
- *Vibrio cholerae* 0139
- Leptospirosis
- Nipah virus disease
- Ebola virus disease
- Hantavirus
- Zika virus

Re-emerging diseases:

- Tuberculosis
- Cholera
- Dengue
- Malaria
- Chikungunya
- Kala-azar
- Meningococcal meningitis
- Diphtheria

Q3. Brief notes on Zika virus.

(ABKUB, 2018)

Ans: Zika virus is a **mosquito-borne flavivirus that was first identified in Uganda in 1947**. Large outbreak was reported from Island of Yak in 2007. Brazil reported an association between Zika virus infection and Guillain-Barré syndrome and also **microcephaly in 2015**.

Problem statement: Transmission of Zika virus in 22 countries and American territories reported by WHO through International travel by mosquito vector. Lack of immunity is an important factor. Disease has not been reported in India though Dengue fever is prevalent in India.

Mode of transmission: It is transmitted through bite of an infected *Aedes* mosquito mainly *Aedes aegypti* transmitted from an infected pregnant mother to baby during pregnancy or at the time of birth.

Clinical feature: The symptoms are clear to Dengue which includes fever, skin rashes, conjunctivitis, musculoskeletal pain, malaise and headache, it last for 2–7 days. History of travel from an endemic areas two weeks preceding the onset of illness. Case fatality is also low.

Diagnosis: Through RT-PCR mostly.

Treatment: Symptomatic treatment, rest, plenty of fluids, use of paracetamol in severe case needs medical care, no vaccine available. NCDC, Delhi and NIV, Pune and other ten additional laboratories would be strengthened by ICMR for RT-PCR

Prevention: Control through Integrated vector management.

SWINE FLU-RELATED QUESTIONS AND ANSWERS

Q4. Describe epidemiology, clinical features, diagnosis, management and prevention and control of Swine Flu (H_1N_1).

(BNMUB, 2015; SAMU, 2011, 2013; NU, 2015; TDMGRMU, 2009; ABKUB, 2010, 2017; RUJH, 2013)

Ans: Epidemiology of Swine flu: Synonyms of “Swine Flu” are Pandemic Influenza or H_1N_1 flu, hog flu, pig flu. Causative agent is H_1N_1 virus responsible for 2009 pandemic. It is a zoonotic disease endemic among swine and rarely seen in humans. According to CDC, a mutant form of H_1N_1 referred to as “Nobel H_1N_1 ” virus was transmitted from pigs to pig handlers several months before the onset of pandemic and later spread among human population.

Major shifts in the make-up of influenza viruses occur every 20 years or so, triggering large epidemics in many parts of the world and may cause thousands of deaths. The next such shift is expected to take place very soon. The epidemic strains of influenza viruses originated from China. The influenza virus is carried by ducks, chickens and pigs and raised in close proximity to one another. Each epidemic was seen due to different strain of viruses. Currently, Avian H_5N_1 is the strain which is contagious among humans. **Pandemic influenza A (H1N1) in 2009** involved 214 countries and took 18,156 lives. They affect all age groups, since older people have not acquired immunity to them from previous infection.

Clinical features among pigs of Swine flu: It is characterized by barking cough, nasal discharge, sneezing, breathing difficulty and going off feed. Death rate is very low among pigs.

Clinical features among humans of Swine flu: They are classical flu like symptoms, such as fever/chills, sore throat, running nose, cough, headache and myalgia. Vomiting and diarrhea are common also.

Avian Influenza (Bird flu)

(ABKUB, 2005, 2008)

It is the disease of bird, caused by a (H_5N_1) virus that can occasionally infect humans having significant exposure to infected birds/poultry. Highly pathogenic avian influenza (HPAI) viruses cause large scale economic loss in poultry sector. HPAI virus results in outbreak among birds.

Clinical features of avian influenza in birds: The features are ruffled feathers, soft shelled eggs, off feeds, sudden drop in egg production, inability to walk, watery diarrhea, fast breathing. Mortality is greater than 5% within few days. **Clinical features of avian influenza in humans:** High grade fever of 104°F , associated with cough, shortness of breath and diarrhea. Lower respiratory tract infection is predominant. Diarrhea occurs in 20% of cases. X-ray chest may show widespread collapse, consolidation and interstitial shadowing. Factor associated with severity of disease are old age, delay in hospitalization, enhanced lower respiratory tract infection and leukopenia. Viral replication resulted in multiorgan failure.

Laboratory diagnosis: For detection of the virus, the preference of sample is found in the following order. Endotracheal aspirate if patient is intubated, oropharyngeal swab, nasopharyngeal swab/secretions are the preferred samples.

All sample should be transported in cold chain at $0-40^\circ\text{C}$ to the designated laboratory quickly. According to WHO, triple packing technique should be applied. The sample should be accompanied by clinical details with a certificate that **the sample is sent for research purpose only and not hazardous to the community.**

It has to be noted that two designated laboratories in India are National Institute of Communicable Diseases (NICD), New Delhi and National Institute of Virology, Pune, Maharashtra, India.

Biosafety measures:

- Clinical specimens should be collected by hospital staff only (not by laboratory staff), wearing personal protective equipment (PPE), such as head cover, goggles, N-95 mask, disposable gloves and disposable apron.

- Proper hand washing of all categories of laboratory staff should be done after handling the materials and leaving the laboratory.

Case management: Symptomatic treatment is given for as that of other seasonal influenza cases. Confirmed cases of H1N1 along with their contacts should be treated and subsequent disinfection is mandatory. The neuraminidase inhibitors comprising **Oseltamivir (Tamiflu)** is mostly used. Oseltamivir (Tamiflu) is available in the form of 75 mg capsule and pediatric suspension is also available in 12 mg per mL after reconstitution. Early treatment within 2 days improves survival. All doses are given twice daily for 5 days.

Q5. All influenza pandemics were caused by influenza virus A and not by B or C. Explain. (WBUHS, 2012)

Ans: When an epidemic is affecting a large proportion of population, occurring over a wide geographic area, such as a section of the nation, the entire nation or continent of the world, it is called pandemic. **Examples:** Pandemics caused by influenza A virus. This virus is unique among the viruses, because it is frequently subjected to antigenic variation, both major and minor. When there is a sudden, complete or major change, it is called antigenic shift. It appears to result from genetic recombination of human with animal or avian virus, providing a major antigenic change. This can cause a major epidemic or pandemic involving most or all age groups. Antigenic changes occur to a lesser degree in B group influenza viruses. Influenza C appears to be antigenically stable, so they cannot cause pandemics.

Q6. What is antigenic shift and antigenic drift?

(ABKUB, 2022; VKSUAB, 2019; RGUHS, 2003; NU, 2014; GNSUB, 2023; GOAU, 2021)

Ans: Antigenic shift and antigenic drift are different degree of antigenic variations seen in the influenza virus. Most commonly seen in type A virus.

a. Antigenic shift:

- It is an abrupt, drastic, discontinuous variations seen in the antigenic structure, resulting in a novel virus stain unrelated antigenically to predecessor strain.
- Major antigenic change in HA (H_2 to H_3) or NA (N_1 to N_3).
- Antibodies to predecessor virus do not neutralize the new variants
- May lead to epidemics or pandemics.

b. Antigenic drift:

- It is a gradual sequential change in the antigenic structure occurring regularly at frequent intervals.
- It results from mutation in the HA and HN genes.
- The new antigens though different from preceding antigen are yet related to them, so that they react with antisera to the predecessor virus strains at least to limited extent.
- May lead to sporadic cases.

Q7. Epidemiology and prevention of Ebola virus disease.

(TDMGRMU, 2016)

Ebola virus disease.

(DU, 2014)

Ans: Ebola virus disease (previously known as Ebola hemorrhagic fever) is most notorious. It has stuck in Africa. Ebola first time appeared in Zaire and Sudan in 1976.

The recent epidemic started in December 2013 in Guinea and spread to South Africa. By September 2014, total 7192 cases were reported with 3286 deaths. Case fatality rate was found as high as 70%.

Clinical features: Sudden onset of fever, intense weakness, muscle pain, headache, sore throat, vomiting, diarrhea, rash, impaired kidney and liver functions and both internal and external bleeding.

Incubation period: 2–21 days and not infective during this period.

Mode of transmission: The virus is transmitted through direct contact with the blood, organs, body secretions or other body fluids of infected animals like chimpanzees, gorillas, monkeys, fruit bats, etc. Human-to-human transmission is through blood or body fluids of an infected symptomatic person or through exposure to objects, such as needles and syringes already contaminated with infected secretions.

But this is not transmitted through air, water or food.

Management: There is no specific treatment. Intensive supportive care is the only measure.

Prevention: Mortality can be reduced and spread of disease can be reduced through specific infection control measures. **Vaccine for the prevention of Ebola virus disease (EVD) (Fig. 20.1):** The US Food and Drug Administration announced today the approval of Ervebo, the first FDA-approved vaccine for the prevention of Ebola virus disease (EVD), caused by Zaire ebolavirus. The first vaccine to be approved in the United States was rVSV-ZEBOV in December 2019.

Type of vaccine: Live attenuated vaccine. It protects Zaire ebolavirus in individuals aged 18 years and older. It is important to note that thaw vial at room temperature until no visible ice is present; do not thaw vial in a refrigerator gently invert vial several times visually inspect for particulate matter and discoloration before use, vaccine is a colorless to slightly brownish-yellow liquid with no particulates visible, use the vaccine immediately after thawing.

Route, site and dose: It is given intramuscular preferably in the deltoid area of the nondominant arm discard unused portion.

Individual less than 18 years and pregnant and lactating mother: Less than 18 years safety and efficacy not established.

Pregnancy: There are no adequate and well-controlled studies in pregnant women, and human data available from clinical trials are insufficient to establish the presence or absence of vaccine-associated risk during pregnancy.

Lactation: Human data are not available to assess the effects on milk production, its presence in breast milk, or its effects on the breastfed child.

Thawed vials: If not used immediately, refrigerate at 2–8°C (35.6–46.4°F) for a total time of no more than 2 weeks and at room temperature (up to 25°C; 77°F) for a total time of no more than 4 hours.



Fig. 20.1: Ebola vaccine.

Q8. Discuss bioterrorism.

(ABKUB, 2018; TRIU, 2022; PBDSUHS, 2017)

Ans: Biological warfare seems to have been existing since 600 BC—Roman Generals poisoned water by dumping rotting animal carcasses for the enemies. In Scythia 400 BC arrows were used dipped in blood. Hannibal in 190 BC venomous snakes in Roman ships. Ukraine in 1346, catapulted bodies of plague victims into the city of Kaffa. In 1954–1967, blankets infested with smallpox were distributed to American Indians during the French and Indian war. 1932, the Japanese experimented on Chinese by using anthrax, cholera and shigellosis. In 1984 in Dallas, salad contaminated with *Salmonella typhimurium* was used to influence the results of election.

Anthrax contaminated letter was posted to politicians. In September 11, 2001, terrorist used nuclear, chemical and biological weapons to attack World Trade Center in New York.

Evolution of chemical and biological weapons:

Phase I: Gaseous chemical like chlorine and phosgene were used in World War I

Phase II: Use of nerve agents—tabun and anthrax and plague in World War II

Phase III: Herbicides were used causing crops destruction

Phase IV: Biotechnological and genetic engineering revolutions are in progress.

Merits:

- Low cost
- Large quantities can be produced in short span of time with small facilities
- Nondetection by routine security system (biosensor)
- Very toxic, small quantities are sufficient to kill large number of persons

Demerits:

- Difficulty in protecting workers during production, transportation and delivery
- Difficulty in quality control, contaminated during growth and harvesting
- Difficult to control once released

Top biological weapons:

- *Bacillus anthracis*
- *Yersinia pestis*
- *Clostridium botulinum*
- *Vibrio cholerae*
- Variola virus

CM20.2: Describe various issues during outbreaks and their prevention.

Q9. Describe various issues during outbreaks and their prevention.**Ans: Issues related to detection of an outbreak:**

Denial: The important reasons for hiding and denying outbreaks could be:

- No skills to investigate
- Additional work
- Press pressure
- Fear of sanctions

Outbreaks are only investigated when there is a large cluster, which shows that the system is reactive only or the system acts under pressure when most cases have occurred or else the system never investigates and denies the occurrence of outbreak.

Remedial measures: Technical training, guidance and motivation of the staff is very important. Investigation methods can be learned and detection becomes easier with practice.

A. Weak or inadequate surveillance system for early detection of outbreaks: Though the IDSP is in place since 2004, the surveillance system for epidemic prone diseases tends to be very weak in ground situation. Medical offices do not write the diagnosis in the OPD register. Few lacunae are discussed below:

- Data is not compiled and not looked into before transmission to district surveillance officers (weekly reports on P, S and L-form).
- Data is not analyzed locally to detect outbreaks and seasonal variations at early stage. Early warning signals, such as clustering of cases or deaths, increase in cases or deaths are mostly ignored.
- Reports on surveillance by various units are not in time and are incomplete.
- Local communities and informants system is poorly developed.

Remedial measures:

- Timely upgradation of IDSP registers
- Strengthening of surveillance systems by supportive supervision and motivation
- Use of locally collected data for planning of program and early response.

B. Issues related to health systems:

- IDSP works through existing health system of village, subcenters, PHCs and CHCs, urban health centers and Sentinel hospitals. In many of the areas, health workforce/human resources are deficient. Thus, the system is not functioning properly as a result early detection of outbreaks and quick response is absent.

- Involvement of private health providers/practitioners: Because of inefficient Government Health System people turn to private health providers and these providers treat over 70% of spells of sickness, hence their capacities for early detection of outbreaks, disease notification and control and prevention must be fully utilized. These providers are need to be provided upgraded national guidelines on control and prevention of outbreaks by organizing short-term training through various professional bodies.

CM20.3: Describe any event important to health of the community.

Q10. What is COVID-19 infection, clinical features of it, different modes of transmission of COVID-19 infection, diagnosis, high-risk groups, discuss its management and prevention.

(WBUHS, 2021; MGUB, 2022; SSUHSA, 2020; ABKUB, 2023; TRIU, 2022; RUJH, 2021; RGUHS, 2024)

Ans: Novel coronavirus (nCoV) is a provisional name given to coronaviruses of medical significance before a permanent name is decided upon.

The name “coronavirus” is derived from Latin corona, meaning “crown” or “wreath”, itself a borrowing from Greek κορώνη korōnē, “garland, wreath”. The scientific name Coronavirus was accepted as a genus name by the International Committee for the Nomenclature of Viruses (later renamed International Committee on Taxonomy of Viruses) in 1971. In December 2019, a pneumonia outbreak was reported in Wuhan, China. On 31 December 2019, the outbreak was traced to a novel strain of coronavirus, which was given the interim name 2019-nCoV by the World Health Organization (WHO), later renamed SARS-CoV-2 by the International Committee on Taxonomy of Viruses.

The COVID-19 pandemic in India is part of the worldwide pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). **The first case of COVID-19 in India, which originated from China, was reported on 30 January 2020.**

Most common symptoms: Fever, dry cough, tiredness

Less common symptoms: Aches and pains, sore throat, diarrhea, conjunctivitis, headache, loss of taste or smell, a rash on skin, or discoloration of fingers or toes

Serious symptoms: Difficulty breathing or shortness of breath, chest pain or pressure, loss of speech or movement, seek immediate medical attention if you have serious symptoms, always call before visiting your doctor or health facility. Some symptoms of COVID-19 can be relatively non-specific; the two most common symptoms are fever (88%) and dry cough (68%). Among those who develop symptoms, approximately one in five may become more seriously ill and have difficulty breathing. Emergency symptoms include difficulty breathing, persistent chest pain or pressure, sudden confusion, difficulty in waking, and bluish face or lips; immediate medical attention is advised if these symptoms are present. Further development of the disease can lead to complications including pneumonia, acute respiratory distress syndrome, sepsis, septic shock, and kidney failure.

People with mild symptoms who are otherwise healthy should manage their symptoms at home.

On average, it takes 5–6 days from when someone is infected with the virus for symptoms to show, however it can take up to 14 days.

Incubation period: As is common with infections, there is a delay, known as the incubation period, between the moment a person first becomes infected and the appearance of the first symptoms. The median incubation period for COVID-19 is 4–5 days. Most symptomatic people experience symptoms within 2–7 days after exposure, and almost all symptomatic people will experience one or more symptoms before days 12.

Different mode of transmission of COVID-19 infection:

- COVID-19 spreads most often when people are physically close.
- It spreads very easily and sustainably through the air, primarily via small droplets or aerosols, as an infected person breathes, coughs, sneezes, sings, or speaks.

- It may also be transmitted via contaminated surfaces, although this has not been conclusively demonstrated.
- Airborne transmission from aerosol formation is suspected to be the main mode of transmission.
- It can spread from an infected person for up to 2 days before they display symptoms, and from people who are asymptomatic.
- Causing airborne transmission particularly in crowded and inadequately ventilated indoor spaces, such as restaurants, nightclubs or choirs.
- People remain infectious for 7–12 days in moderate cases, and up to two weeks in severe cases
- Kissing, physical intimacy and other forms of direct contact can easily transmit the virus and thus lead to COVID-19 in people exposed to such contact.
- It may be possible that a person can get COVID-19 through indirect contact by touching a contaminated surface or object, and then touching their own mouth, nose, or possibly their eyes, though this is not thought to be the main way the virus spreads.
- There currently is no significant evidence of COVID-19 virus transmission through feces, urine, breast milk, food, wastewater, drinking water, animal disease vectors, or from mother to baby during pregnancy, although research is ongoing and caution is advised.

Diagnosis: The standard method of diagnosis is by real-time reverse transcription polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab. Results are generally available within a few hours to 2 days. Antibody tests may be most accurate 2–3 weeks after a person's symptoms start.

High-risk groups:

- Front line workers like physicians, nurses, health workers and safai karamchari are more prone to develop COVID-19 infection
- The following disease and condition may cause severe form of COVID-19 infection:
 - *Cancer:* Treatments for many types of cancer weaken body's ability to fight
 - Chronic kidney disease
 - Chronic lung diseases, including COPD (chronic obstructive pulmonary disease), asthma (moderate-to-severe), interstitial lung disease, cystic fibrosis, and pulmonary hypertension
 - Dementia or other neurological conditions
 - Diabetes (type 1 or type 2)
 - Down syndrome
 - Heart conditions, such as heart failure, coronary artery disease, cardiomyopathies or hypertension
 - Stroke or cerebrovascular disease, which affects blood flow to the brain
 - HIV infection
 - *Immunocompromised state:* Many conditions and treatments can cause a person to be immunocompromised or have a weakened immune system. Primary immunodeficiency is caused by genetic defects that can be inherited. Prolonged use of corticosteroids or other immune weakening medicines can lead to secondary or acquired immunodeficiency.
 - *Liver disease:* Chronic liver disease, such as alcohol-related liver disease, nonalcoholic fatty liver disease, and especially cirrhosis, or scarring of the liver.
 - *Overweight and obesity:* Overweight (defined as a body mass index (BMI) $>25 \text{ kg/m}^2$ but $<30 \text{ kg/m}^2$), obesity (BMI $\geq 30 \text{ kg/m}^2$ but $<40 \text{ kg/m}^2$), or severe obesity (BMI of $\geq 40 \text{ kg/m}^2$) are more likely to get severely ill from COVID-19. The risk of severe COVID-19 illness increases sharply with elevated BMI.
 - Pregnancy are more likely to get severely ill from COVID-19 compared with non-pregnant people.
 - Sickle cell disease or thalassemia
 - Smoking, current or former can make more likely to get severely ill from COVID-19. If you currently smoke, quit. If you used to smoke, do not start again. If you have never smoked, do not start
 - Solid organ or blood stem cell transplant
 - Substance use disorders, such as alcohol, opioid, or cocaine use disorder

Prevention: Recommended measures to prevent infection include frequent social distancing, quarantine, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. Social distancing **and the** wearing of cloth face masks, surgical masks, respirators, or other face coverings **are controls for droplet transmission.**

Personal protective equipment: For healthcare professionals who may come into contact with COVID-19 positive bodily fluids, using personal protective coverings on exposed body parts improves protection from the virus.

Face masks/Mask is the best vaccine for COVID-19 disease.

(AKUB, 2022)

The World Health Organization (WHO) and most government health agencies [such as the US Centers for Disease Control and Prevention (CDC), the UK National Health Service (NHS), or the New Zealand Ministry of Health] recommend individuals wear non-medical face coverings in public settings where there is an increased risk of transmission and where social distancing measures are difficult to maintain. Face coverings limit the volume and travel distance of expiratory droplets dispersed when talking, breathing, and coughing. Many countries and local jurisdictions encourage or mandate the use of face masks or cloth face coverings by members of the public to limit the spread of the virus. Masks are also strongly recommended for those who may have been infected and those taking care of someone who may have the disease.

Social distancing: Social distancing strategies aim to reduce contact of infected persons with large groups by closing schools and workplaces, restricting travel, and canceling large public gatherings. Distancing guidelines also include that people stay at least 2 meters (6.6 ft) apart.

Hand-washing and hygiene: WHO also recommends that individuals wash hands often with soap and water for at least 20 seconds, especially after going to the toilet or when hands are visibly dirty, before eating and after blowing one's nose. The CDC recommends using an alcohol-based hand sanitizer with at least 60% alcohol, but only when soap and water are not readily available.

Co-morbidities: Most of those who die of COVID-19 have pre-existing (underlying) conditions, including hypertension, diabetes mellitus, and cardiovascular disease.

Complications: It may include pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, septic shock, and death. Cardiovascular complications may include heart failure, arrhythmias, heart inflammation, and blood clots. Approximately 20–30% of people who present with COVID-19 have elevated liver enzymes reflecting liver injury. Neurologic manifestations include seizure, stroke, encephalitis, and Guillain-Barré syndrome (which includes loss of motor functions). Following the infection, children may develop pediatric multisystem inflammatory syndrome, which has symptoms similar to Kawasaki disease, which can be fatal.

Management: People are managed with supportive care, which may include fluid therapy, oxygen support, and supporting other affected vital organs.

Remdesivir was approved for medical use in the United States in October 2020. It is the first treatment for COVID-19 to be approved by the US Food and Drug Administration (FDA). It is indicated for use in adults and adolescents [aged twelve years and older with body weight at least 40 kilograms (88 lb)] for the treatment of COVID-19 requiring hospitalization.

Several existing medications are being evaluated for the treatment of COVID-19, including **remdesivir, chloroquine, hydroxychloroquine, lopinavir/ritonavir, and lopinavir/ritonavir combined with interferon beta, azithromycin, doxycycline, favipiravir, dexamethasone, heparin and tocilizumab.**

Convalescent plasma therapy: Transferring purified and concentrated antibodies produced by the immune systems of those who have recovered from COVID-19 to people who need them is being investigated as a nonvaccine method of passive immunization. The safety and effectiveness of convalescent plasma as a treatment option requires further research.

Available vaccines against COVID-19: (AKUB, 2022; SSUHSA, 2022; VBUJH, 2023; GOAU, 2021; RUJH, 2024)

Name of the vaccine	Type	Company	Doses/Day	Route	Beneficiary
Covaxin	Inactivated novel corona virus	Indigenous—Bharat Biotech (Hyderabad)	2 doses (0, 28)	I/M 0.5 mL	6 years and above
Covishield	Vector (Ch Ad virus) based spike protein	University of Oxford and AstraZeneca and Serum Institute of India (SII)	2 doses (0, 84)	I/M 0.5 mL	18 years and above
Sputnik V	Vector (Ch Ad virus) based spike protein	Gamaleya research institute, Russia	2 doses (0, 21)	I/M 0.5 mL	18 years and above
iNOVACC	Vector vaccine (adenovirus)	Bharat Biotech	2 doses (0, 28)	Intranasal 0.5 mL (8 drops)	18 years and above
ZyCoV-D	DNA based	Zydus Cadila (Ahmedabad)	3 doses (0, 28, 56) of 2 mg each	Needle free applicator (Jet)	12 years and above
mRNA-1273 vaccine	mRNA	USA-based Moderna	2 doses (0, 28)	I/M 0.5 mL	5 years and above
Tozinameran BNT162b2 vaccine	mRNA	USA-based Pfizer–BioNTech	2 doses (0, 28)	I/M 0.5 mL	5 years and above
Corbevax	Recombinant protein Subunit vaccine	Biological E Hyderabad	2 doses (0, 28)	I/M 0.5 mL	5 years above
Covovax	Recombinant protein Subunit vaccine	NOVAVAX (American) and Serum Institute of India (SII)	2 doses (0, 21)	I/M 0.5 ml	12 years and above

Covid 19 vaccines commonly used in India:

- Covishield
- Covaxin
- Corbevax

CM20.4: Demonstrate awareness about laws pertaining to practice of medicine such as Clinical Establishments Act and Human Organ Transplantation Act and its implications.

Q11. Demonstrate awareness about laws pertaining to practice of medicine such as Clinical Establishments Act and Human Organ Transplantation Act and its implications.

Ans: Transplantation of Human Organ Act, 1994, amended in 2011 and 2014, now known as THOTA:

Implications: A large number of persons suffer from end-stage organ failure, they require transplantation. There is huge gap between the requirement of organs and their availability. There is also a threat of commercial dealing in organs. Transplantation of Human Organs Act, 1994, was, therefore, enacted to regulate removal, storage and transplantation of human organs for therapeutic purposes and for prevention of commercial dealings in human organs. The Act has been adopted by all states and UTs except Jammu and Kashmir, Andhra Pradesh and Telangana. The amended Act and Rules thereunder provide for inclusion of tissues in the Act along with organs. Act expands the definition of “near relatives” to include grand children and grand parents.

Implementation of Act: GOI is implementing National Organ Transplant Programme (NOTP) to retrieve, store and transport of organs, training of manpower and awareness generation to promote organ donation from deceased persons. There is need to promote organ donation from deceased (cadaveric) donors rather than relying on living donors, because of commercial trading and increased risk of health of living donors. Under the program, an apex level organization, viz, National Organ and Tissue Transplant Organization (NOTTO) has been set up at Safdarjung Hospital at New Delhi.

Clinical Establishments Act (CEA), 2010: The Act is for registration and regulation of the clinical establishments (excepts those of armed forces), with an objective to prescribe minimum standards of facilities and services. Recognized qualifications of person in-charge of clinical establishment have been specified. The Ministry of Health and Family Welfare has notified clinical establishments.

A. National Council for Clinical Establishments (NCCE): Under the chairmanship of DGHS, this body performs the following functions. State councils for clinical establishments have been also constituted.

- Compiling and Publishing National Register of Clinical establishments
- Classify the clinical establishment into different categories
- Develop the minimum standards for establishments and their periodic review
- Determine the 1st set of standards for ensuring proper health care
- Collect statistics on regular basis

B. Implementation:

- Facility for online registration for clinical establishments
- Operational guidelines for minimum standards have been issued for implementing states
- Standard treatment guidelines (STGs) under National Health Programs have been compiled and uploaded
- STGs for Ayurveda have been compiled
- List of medical treatment and standard template of costing of procedures and services has been prepared and states have been advised to use it.

MULTIPLE CHOICE QUESTIONS (MCQs)

1. **Incubation period of SARS is:** (BNMUB, 2002)
 a. 3–10 days b. 15–18 days c. 30 days d. None of the above
2. **Incubation period of meningococcal meningitis is:** (BNMUB, 2002, 2006)
 a. 3–4 days b. 5–8 days c. 30 days d. None of the above
3. **Ebola virus disease is transmitted by:** (YSRUHSAP, 2023)
 a. Droplet infection b. Droplet nuclei infection
 c. Direct contact with body fluids d. Fomites
4. **Following health event did not occur in last 5 years:** (AKUB, 2023)
 a. MCI is replaced by NMC
 b. RNTCP renamed NTEP
 c. Elimination of Polio from our country
 d. Covid Vaccine [Covaccine] produced by Bharat Biotech
5. **Which of the following re-emerging diseases led to large-scale deaths due to pneumonias in India?** (TRIU, 2023)
 a. COVID-19 b. Swine (H_1N_1) influenza
 c. Plague d. Tuberculosis
6. **Major reason for H_5N_1 not to become a global pandemic is:** (RUJH, 2024)
 a. Route of transmission is not respiratory
 b. Man to man transmission is rare
 c. Does not cause serious disease among humans
 d. Restricted to few countries only

Answers:

1.	a	2.	a	3.	c	4.	c	5.	b	6.	b								
----	---	----	---	----	---	----	---	----	---	----	---	--	--	--	--	--	--	--	--

Community Medicine Buster

Salient Features

- Based on latest CBME curriculum
- Questions and Answer format
- Consists of 22 chapters
- 10 years' Long Essay Questions and Short Notes up to 2024 from 30 universities across India
- 1,000+ MCQs distributed within the chapter with AETCOM-related questions
- Current information on National Programs incorporated as far as possible though it is changing from time to time for the need of the country.

Gautam Sarker MBBS MD (SPM) is a Professor, Department of Community Medicine, MGM Medical College and LSK Hospital, Kishanganj, Bihar, India. He obtained his MD (SPM) degree from All India Institute of Hygiene and Public Health, Kolkata, West Bengal, India under the University of Calcutta in 2001. Afterwards he worked in International Organizations like UNICEF, Population Services International and CARE in different capacities for about 10 years. He published 29 original articles in reputed international and national indexed journals. He is examiner for Bhupendra Narayan Mandal University (BNMU) Madhepura, Bihar; West Bengal University of Health Sciences (WBUHS), Kolkata, West Bengal, India; Aryabhatta Knowledge University (AKU), Patna, Bihar; Srimanta Sankaradeva University of Health Sciences (SSUHS), Assam, India and other Universities of India.

Palash Das MBBS DPH MD FAIMER Fellow (CMCL) is a Professor, Department of Community Medicine and Medical Superintendent-cum-Vice-Principal, Rampurhat Government Medical College and Hospital, Rampurhat, West Bengal, India. He obtained his undergraduate and the postgraduate degree from the University of Calcutta. Postgraduate training was taken from All India Institute of Hygiene and Public Health, Kolkata.

He has worked in West Bengal Health Services (WBHS) and later on in health administration, West Bengal Public Health and Administrative Service (WBPHAS) for 12 years and then he joined to West Bengal Medical Education Services (WBMES). He was posted in different medical colleges under West Bengal Government.

He has published 75 original articles in different reputed national and international indexed journals and different local magazines. He is editorial board member of many reputed academic journals. He is executive member of many local and national academic and nongovernment organizations. He is examiner for WBUHS and different universities of other provinces.

Printed in India



Available at all medical bookstores
or buy online at www.ejaypee.com



JAYPEE BROTHERS
Medical Publishers (P) Ltd.
EMCA House, 23/23-B, Ansari Road,
Daryaganj, New Delhi - 110 002, INDIA
www.jaypeebrothers.com

Join us on [facebook.com/JaypeeMedicalPublishers](https://www.facebook.com/JaypeeMedicalPublishers)
Follow us on [instagram.com/JaypeeMedicalPublishers](https://www.instagram.com/JaypeeMedicalPublishers)

Shelving Recommendation
COMMUNITY MEDICINE

ISBN 978-93-5696-994-0

